Results 201 to 210 of about 94,066 (344)

Cre-dependent DREADD (Designer Receptors Exclusively Activated by Designer Drugs) mice. [PDF]

Genesis, 2016
Zhu H, Aryal DK, Olsen RH, Urban DJ, Swearingen A, Forbes S, Roth BL, Hochgeschwender U.   +7 more
europepmc   +1 more source

Analysis of New Designer Drugs in Post-Mortem Blood Using High-Resolution Mass Spectrometry [PDF]

, 2014
Daniel Pasin, Sergei Bidny, Shanlin Fu
openalex   +1 more source

ATF4‐mediated stress response as a therapeutic vulnerability in chordoma

Molecular Oncology, EarlyView.
We screened 5 chordoma cell lines against 100+ inhibitors of epigenetic and metabolic pathways and kinases and identified halofuginone, a tRNA synthetase inhibitor. Mechanistically halofuginone induces an integrated stress response, with eIF2alpha phosphorylation, activation of ATF4 and its target genes CHOP, ASNS, INHBE leading to cell death ...
Lucia Cottone, James Dunford, Eleanor Calcutt, Vicki Gamble, Filiz Senbabaoglu Aksu, Lorena Ligammari, Georgina Wherry, Giorgia Gaeta, John C. Christianson, Adrienne M. Flanagan, Udo Oppermann, Adam P. Cribbs   +11 more
wiley   +1 more source

Toxicokinetics of Emerging Drugs of Abuse : In vivo and in vitro studies on the metabolic fate of the cocaine-derived designer drug dimethocaine

, 2014
Carina Lindauer
openalex   +1 more source

Designer DNA-Binding Drugs: The Crystal Structure of a Meta-Hydroxy Analogue of Hoechst 33258 Bound to d(CGCGAATTCGCG)2 [PDF]

, 1996
George R. Clark, C.J. Squire, Emily J. Gray, Werner Leupin, Stephen Neidle   +4 more
openalex   +1 more source

Developing evidence‐based, cost‐effective P4 cancer medicine for driving innovation in prevention, therapeutics, patient care and reducing healthcare inequalities

Molecular Oncology, EarlyView.
The cancer problem is increasing globally with projections up to the year 2050 showing unfavourable outcomes in terms of incidence and cancer‐related deaths. The main challenges are prevention, improved therapeutics resulting in increased cure rates and enhanced health‐related quality of life.
Ulrik Ringborg, Joachim von Braun, Julio Celis, Anton Berns, Michael Baumann, Tit Albreht, Nancy Abou‐Zeid, Vanderlei Bagnato, Christian Brandts, Chien‐Jen Chen, Massimiliano di Pietro, Manjit Dosanjh, Thomas Dubois, Alexander Eggermont, Angelika Eggert, Ingemar Ernberg, Sara Faithfull, Johannes Förner, Stefan Fröhling, Manuel Heitor, Leroy Hood, Wei Jiang, Bengt Jönsson, Ravi Kannan, Maria Leptin, Su Li, Peter Lindgren, Douglas Lowy, Jun Ma, Alex Markham, Péter Nagy, Simon Oberst, M. Iqbal Parker, Danielle Rodin, Kevin Ryan, Joachim Schüz, Richard Sullivan, Josep Tabernero, Peter Turkson, Oliver Várhelyi, Harold Varmus, Chijie Wang, Elisabete Weiderpass, Nils Wilking   +43 more
wiley   +1 more source

Decoding PACAP signaling: Splice variants, pathways and designer drugs

Zoe Tasma, Debbie L. Hay
openalex   +1 more source

Fentanyl and its derivatives as a group of new psychoactive substances (designer drugs)

, 2018
Marcin Zawadzki, Karolina Nowak
openalex   +1 more source

Cell surface interactome analysis identifies TSPAN4 as a negative regulator of PD‐L1 in melanoma

Molecular Oncology, EarlyView.
Using cell surface proximity biotinylation, we identified tetraspanin TSPAN4 within the PD‐L1 interactome of melanoma cells. TSPAN4 negatively regulates PD‐L1 expression and lateral mobility by limiting its interaction with CMTM6 and promoting PD‐L1 degradation.
Guus A. Franken, Andrea Abel Gutierrez, Imke van Rossum, Cornelia G. Spruijt, Michiel Vermeulen, Guido van Mierlo, Blanca Scheijen, Annemiek B. van Spriel   +7 more
wiley   +1 more source

Metabolism of α-PHP and α-PHPP in humans and the effects of alkyl chain lengths on the metabolism of α-pyrrolidinophenone-type designer drugs. [PDF]

Forensic Toxicol, 2018
Matsuta S, Shima N, Kakehashi H, Kamata H, Nakano S, Sasaki K, Kamata T, Nishioka H, Miki A, Zaitsu K, Tsuchihashi H, Katagi M.   +11 more
europepmc   +1 more source